Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma

HFCAS OpenIR

	Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma
其他题名	Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma
	2016
发表期刊	CHINESE JOURNAL OF CANCER
ISSN	1000-467X
摘要	Background: Salvage treatment for locally recurrent nasopharyngeal carcinoma (NPC) is complicated and relatively limited. Radiotherapy, combined with effective concomitant chemotherapy, may improve clinical treatment outcomes. We conducted a phase II randomized controlled trial to evaluate the efficacy of intensity-modulated radiotherapy with concomitant weekly cisplatin on locally recurrent NPC.
其他摘要	Background Salvage treatment for locally recurrent nasopharyngeal carcinoma (NPC) is complicated and relatively limited. Radiotherapy, combined with effective concomitant chemotherapy, may improve clinical treatment outcomes. We conducted a phase II randomized controlled trial to evaluate the efficacy of intensity-modulated radiotherapy with concomitant weekly cisplatin on locally recurrent NPC. Methods Between April 2002 and January 2008, 69 patients diagnosed with non-metastatic locally recurrent NPC were randomly assigned to either concomitant chemoradiotherapy group ( n =34) or radiotherapy alone group ( n =35). All patients received intensity-modulated radiotherapy. The radiotherapy dose for both groups was 60Gy in 27 fractions for 37days (range 23–53days). The concomitant chemotherapy schedule was cisplatin 30mg 2 by intravenous infusion weekly during radiotherapy. Results The median follow-up period of all patients was 35months (range 2–112months). Between concomitant chemoradiotherapy and radiotherapy groups, there was only significant difference in the 3-year and 5-year overall survival (OS) rates (68.7% vs. 42.2%, P =0.016 and 41.8% vs. 27.5%, P =0.049, respectively). Subgroup analysis showed that concomitant chemoradiotherapy significantly improved the 5-year OS rate especially for patients in stage rT3–4 (33.0% vs. 13.2%, P =0.009), stages III–IV (34.3% vs. 13.2%, P =0.006), recurrence interval >30months (49.0% vs. 20.6%, P =0.017), and tumor volume >26cm 3 (37.6% vs. 0%, P =0.006). Conclusion Compared with radiotherapy alone, concomitant chemoradiotherapy can improve OS of the patients with locally recurrent NPC, especially those with advanced T category (rT3–4) and stage (III–IV) diseases, recurrence intervals >30months, and tumor volume >26cm 3 .
关键词	CONCURRENT CHEMORADIOTHERAPY PROGNOSTIC-FACTORS RADIATION-THERAPY NECK-CANCER REIRRADIATION CHEMOTHERAPY SURVIVAL METAANALYSIS RETREATMENT HEAD Recurrence Nasopharyngeal carcinoma Intensity-modulated radiation therapy Concomitant chemoradiotherapy Cisplatin
收录类别	CSCD
语种	英语
CSCD记录号	CSCD:5690104
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/61847
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma[J]. CHINESE JOURNAL OF CANCER,2016,35.
APA	(2016).Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma.CHINESE JOURNAL OF CANCER,35.
MLA	"Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma".CHINESE JOURNAL OF CANCER 35(2016).